A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Phase 3
18+
12 sites in CA, FL, KY +5
What this study is about
This Phase 3 study is testing Irinotecan in people with pancreatic adenocarcinoma. The primary outcome being measured is Overall Survival (OS).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
irinotecan, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), oxaliplatin, fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells)
injection (Injection), oral (Oral Capsule)
Primary: Overall Survival (OS)
Secondary: Change from baseline in EORTC QLQ-C30, Change from baseline in EORTC QLQ-PAN26, Change from baseline in EuroQol 5-dimensional 5-level version (EQ-5D-5L), Change from baseline in Patient Global Impression of Change (PGIC)., Change from baseline in Patient Global Impression of Severity PGIS, Number of Participants with Adverse Events (AEs), Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status., Number of Participants with Serious Adverse Events (SAEs)
Oncology